Skip to main content
Article
Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission
World Neurosurgery (2018)
  • Garni Barkhoudarian, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA
  • Sheri K. Palejwala, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA
  • Ronke Ogunbameru, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA
  • Hua Wei, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA
  • Amalia Eisenberg, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA
  • Daniel F. Kelly, Pacific Neuroscience Institute, John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA
Publication Date
October 1, 2018
DOI
10.1016/j.wneu.2018.07.082
Citation Information
Garni Barkhoudarian, Sheri K. Palejwala, Ronke Ogunbameru, Hua Wei, et al.. "Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission" World Neurosurgery Vol. 118 (2018) p. 118 - 124
Available at: http://works.bepress.com/daniel-kelly/2/